Skip to content
Screener

Nurix Therapeutics, Inc. NRIX Financing Cash Flow

Financing Cash Flow at other companies

Arvinas logo
ArvinasARVN
-$100K0.0%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$14.42M-94.1%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
$3.21M+780%
Septerna, Inc. logo
Septerna, Inc.SEPN
$333K+405%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$84.33M+6,037%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$411.17M+66,004%

Other financials

Income statement

See full
Revenue$9.0M-79.5%
Operating income-$94.2M-95.0%
Net income-$89.5M-106%
EPS (diluted)-$0.81-55.8%

Balance sheet

See full
Cash & equivalents$68.7M-19.4%
Total debt$58.1M+12.0%
Total equity$402.6M-10.0%
Total assets$535.5M-9.5%

Cash flow

See full
Operating cash flow-$96.6M-52.9%
CapEx$1.9M-27.6%
Free cash flow-$98.5M-49.6%

Valuation

See full
Market cap$2.62B+227%
Enterprise value$2.61B+240%
P/S71.2×+62.1×

Profitability

See full
Operating margin-982.4%-1,538pp
Net margin-928.4%-1,403pp
FCF margin-378.7%+24.1pp

Returns & leverage

See full
Return on equity-80.3%+113pp
Debt / equity0.1×0.0×
Current ratio6.3×-0.5×

Where this comes from

Reported directly by Nurix Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Nurix Therapeutics, Inc.’s 10-Q, filed July 9, 2026.

Filed
Jul 9, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001549595-26-000040
Line itemSix Months Ended May 31, 2026Six Months Ended May 31, 2025
Proceeds from exercise of stock options441227
Proceeds from issuance of common stock under employee stock purchase plan1,5961,252
Proceeds from issuances of common stock in “at the market” financing, net of issuance costs18,004
Net cash provided by financing activities20,0411,479
Net decrease in cash, cash equivalents and restricted cash(179,275)(25,737)
Cash, cash equivalents and restricted cash at beginning of period247,928110,898
Cash, cash equivalents and restricted cash at end of period$68,653$85,161
Supplemental disclosures of non-cash investing and financing activities:

Item 1. Financial Statements (Unaudited)

FAQ

What is Nurix Therapeutics, Inc.'s financing cash flow?
Nurix Therapeutics, Inc. (NRIX) reported financing cash flow of $66K in Q1 2026.
How has Nurix Therapeutics, Inc.'s financing cash flow changed year-over-year?
Nurix Therapeutics, Inc.'s financing cash flow increased by 1000.0% year-over-year, from $6K to $66K.
What is the long-term trend for Nurix Therapeutics, Inc.'s financing cash flow?
Over 4 years (2021 to 2025), Nurix Therapeutics, Inc.'s financing cash flow has grown at a 11.6% compound annual growth rate (CAGR), from $153.88M to $238.64M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Nurix Therapeutics, Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude